title: Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation.
authors.forename: Norbert
authors.initials: N
authors.lastname: Kovacs
authors.forename: Jozsef
authors.initials: J
authors.lastname: Janszky
authors.forename: Ferenc
authors.initials: F
authors.lastname: Nagy
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000191:economics / Q000627:therapeutic use; D052160:Benzothiazoles / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D018491:Dopamine Agonists / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000191:economics* / Q000627:therapeutic use*; D008390:Markov Chains; D018803:Models, Economic; D008996:Monoamine Oxidase Inhibitors / Q000191:economics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000191:economics*; D000077487:Pramipexole; D006113:United Kingdom
chemical_list: D000978:Antiparkinson Agents; D052160:Benzothiazoles; D018491:Dopamine Agonists; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; C031967:rasagiline; D000077487:Pramipexole